New combo therapy targets liver tumors in rare eye cancer
NCT ID NCT04283890
First seen Sep 30, 2025 · Last updated May 19, 2026 · Updated 30 times
Summary
This study tests a combination of immunotherapy drugs (ipilimumab and nivolumab) plus a chemotherapy drug (melphalan) given directly to the liver for people with advanced uveal melanoma that has spread, especially to the liver. The goal is to see if this approach is safe and can help control the cancer in both the liver and other organs. About 83 adults aged 18-75 with no prior systemic treatment are participating.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UVEAL MELANOMA, METASTATIC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Leiden University Medical Center
Leiden, South Holland, 2333 ZA, Netherlands
Conditions
Explore the condition pages connected to this study.